Genetic variation in the receptor for advanced glycation end-products (RAGE) gene and ischaemic stroke

Authors

  • S. Olsson,

    1. Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    Search for more papers by this author
  • K. Jood

    Corresponding author
    • Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    Search for more papers by this author

Correspondence: K. Jood, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Per Dubbsgatan 14, 413 45 Göteborg, Sweden (tel.: +46 31 3429052; fax: +46 31 842160; e-mail: katarina.jood@neuro.gu.se).

Abstract

Background and purpose

The multi-ligand receptor for advanced glycation end-products (RAGE, alias AGER) is suggested to contribute to the pathogenesis of vascular disease, but its potential role in stroke is unclear. The aim of this study was to investigate whether genetic variation in RAGE gene is associated with ischaemic stroke (IS).

Methods

The Sahlgrenska Academy Study on Ischaemic Stroke comprises 844 Caucasian patients with first ever (n = 732) and recurrent (n = 112) IS, and 668 Caucasian controls. Three tagSNPs were selected to capture genetic variation in the RAGE gene. IS subtypes were determined using TOAST criteria.

Results

One SNP, rs1035798, showed significant association with the subtype of small-vessel disease (SVD) after correction for multiple testing (OR 1.56, 95% CI 1.16–2.09), adjusted P-value < 0.05). This association was independent of hypertension, diabetes and smoking. None of the SNPs was associated with overall IS.

Conclusion

In this sample of patients with IS, genetic variation in RAGE is associated with the IS subtype SVD, but not overall IS.

Ancillary